NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
(Total Views: 140)
Posted On: 08/02/2023 4:32:14 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Designing Human Clinical Study of DehydraTECH-CBD for Weight Loss, Diabetes Control
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today reported its intention to conduct a human clinical study to examine DehydraTECH-CBD for purposes of diabetes control and weight loss. Lexaria previously announced that, in its pre-clinical diabetes study DIAB-A22-1 in obese diabetic-conditioned animals, DehydraTECH-CBD achieved each of the following: lowered blood glucose levels by 19.9%; lowered overall body weight by 7% sustained over eight weeks; statistically significant increase in locomotor activity; lowered triglyceride levels by more than 25%; and lowered blood urea nitrogen levels by 27.9%. As a result of the very successful pre-clinical results, Lexaria is planning to undertake a diabetes clinical study to investigate whether any of these improvements are also evidenced in humans. Study design is currently underway by the company, which will be followed with submission to an independent review board to gain necessary approvals.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today reported its intention to conduct a human clinical study to examine DehydraTECH-CBD for purposes of diabetes control and weight loss. Lexaria previously announced that, in its pre-clinical diabetes study DIAB-A22-1 in obese diabetic-conditioned animals, DehydraTECH-CBD achieved each of the following: lowered blood glucose levels by 19.9%; lowered overall body weight by 7% sustained over eight weeks; statistically significant increase in locomotor activity; lowered triglyceride levels by more than 25%; and lowered blood urea nitrogen levels by 27.9%. As a result of the very successful pre-clinical results, Lexaria is planning to undertake a diabetes clinical study to investigate whether any of these improvements are also evidenced in humans. Study design is currently underway by the company, which will be followed with submission to an independent review board to gain necessary approvals.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼